Clinical Trials Browser

Phase 1/2 × NIH × Rhabdomyosarcoma, Alveolar × Clear all

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Phase 1/2 Terminated

14 enrolled 17 charts

Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00923351 2018-06-15

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

Phase 1/2 Completed

44 enrolled 13 charts

CNSSarcoma

Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal, Neuroectodermal Tumors, Primitive, Peripheral

Clinical Trials

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma